NexImmune Raises $23 Million to Advance Endogenous Cellular ImmunoTherapy into Clinical Development – GlobeNewswire (press release)
|
NexImmune Raises $23 Million to Advance Endogenous Cellular ImmunoTherapy into Clinical Development
GlobeNewswire (press release) GAITHERSBURG, Md., Jan. 02, 2018 (GLOBE NEWSWIRE) — NexImmune, an emerging leader in the field of antigen-directed immunotherapy, announced the closing of a Series A financing co-led by new investor ArrowMark Partners and existing investor Barer & Son … |
